Indicators on Clinical trial recruitment for ABBV-744 study You Should Know
In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs.- "Our study exposed the vital part in the KLF16/MYC regulatory axis in modulating